172734-75-7

Upstream product

• 182621-50-7 Acetic acid 3-[3-(3,4-dichloro-phenyl)-2,6-dioxo-piperidin-3-yl]-propyl ester 
• 146395-97-3 4-Cyano-4-(3,4-dichloro-phenyl)-7-(tetrahydro-pyran-2-yloxy)-heptanoic acid ethyl ester 
• 146395-98-4 5-tetrahydropyranyloxypropyl-5-(3,4-dichlorophenyl)piperidone 
• 146395-99-5 3-(3,4-Dichloro-phenyl)-3-[3-(tetrahydro-pyran-2-yloxy)-propyl]-piperidine 
• 3218-49-3 3,4-dichloro-benzeneacetonitrile 
• 146396-02-3 {3-(3,4-Dichloro-phenyl)-3-[3-(tetrahydro-pyran-2-yloxy)-propyl]-piperidin-1-yl}-phenyl-methanone 
• 146395-96-2 2-(3,4-dichloro-phenyl)-5-(tetrahydro-pyran-2-yl-oxy)-pentanenitrile 
• 182621-49-4 4-Cyano-4-(3,4-dichloro-phenyl)-7-(tetrahydro-pyran-2-yloxy)-heptanoic acid 

Downstream Products

• 172734-92-8 osanetant 
• 182621-57-4 {3-(3,4-Dichloro-phenyl)-3-[3-(4-methylamino-4-phenyl-piperidin-1-yl)-propyl]-piperidin-1-yl}-phenyl-methanone 
• 172734-92-8 (S)-(N)-(1-(3-(1-benzoyl-3(3,4-dichlorophenyl)piperidin-3-yl)propyl)-4-phenylpiperidin-4-yl)-N-methylacetamide 
• 146396-03-4 1-benzoyl-3-(3,4-dichlorophenyl)-3-(3-methane-sulphonyloxypropyl)piperidine 

Relevant academic research and scientific papers

Discovery of bioavailable 4,4-disubstituted piperidines as potent ligands of the chemokine receptor 5 and inhibitors of the human immunodeficiency virus-1

We describe robust chemical approaches toward putative CCR5 scaffolds designed in our laboratories. Evaluation of analogues in the 125I-[MIP-1β] binding and Ba-L-HOS antiviral assays resulted in the discovery of 64 and 68 in the 4,4-disubstitited piperidine class H, both potent CCR5 ligands (pIC50 = 8.30 and 9.00, respectively) and HIV-1 inhibitors (pIC50 = 7.80 and 7.84, respectively, in Ba-L-HOS assay). In addition, 64 and 68 were bioavailable in rodents, establishing them as lead molecules for further optimization toward CCR5 clinical candidates.

Human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them

PCT No. PCT/FR96/01416 Sec. 371 Date Mar. 12, 1998 Sec. 102(e) Date Mar. 12, 1998 PCT Filed Sep. 13, 1996 PCT Pub. No. WO97/10211 PCT Pub. Date Mar. 20, 1997Compounds of formula (I), a method for obtaining them and pharmaceutical compositions containing them are described. The compounds are useful as human NK3 receptor antagonists.

3-alkyl-3-phenyl-piperidines

PCT No. PCT/US97/15443 Sec. 371 Date Jan. 22, 1998 Sec. 102(e) Date Jan. 22, 1998 PCT Filed Sep. 2, 1997 PCT Pub. No. WO98/11090 PCT Pub. Date Mar. 19, 1998The small nonpeptides of the instant invention are tachykinin antagonists of formula or a pharmaceutically acceptable salt thereof wherein: R1 is straight or branched alkyl of from 5 to 15 carbon atoms, aryl, or heteroaryl; R2 is hydrogen, hydroxy, amino, or thiol; R3 is aryl, arylsulfonylmethyl, or saturated or unsaturated heterocycle; R4 is from 1 to 4 groups each independently selected from halogen, alkyl, hydroxy, and alkoxy; n is an integer of from 2 to 6; and the carbon atom of (CH2)n group can be replaced by oxygen, nitrogen, or sulphur. The compounds are highly selective and functional NK3 antagonists expected to be useful in the treatment of pain, depression, anxiety, panic, schizophrenia, neuralgia, addiction disorders, inflammatory diseases, gastrointestinal disorders, vascular disorders, and neuropathological disorders.

High affinity, selective neurokinin 2 and neurokinin 3 receptor antagonists from a common structural template

High affinity, selective hNK2 or hNK3 ligands can be prepared from the common template 1 in a few simple chemical operations. The hNK3 ligands 3 antagonise the calcium mobilisation caused by activation of hNK3 receptors expressed in CHO cells as measured using fura-2 microspectrofluorimetry.

A reliable and efficient synthesis of SR 142801

A convenient synthesis of the potent human NK-3 receptor antagonist SR 142801, (S)-(+)-N-{{3-[1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]prop-1 -yl}-4-phenylpiperidin-4-yl}-N-methylacetamide [(S)-(+)-(15)], is described. Improvements over the previously reported procedure are the preparation of the intermediate 5 via the novel imide 3 and subsequent reaction with the nucleophile 14, which reacts, regioselectively, at the endocyclic nitrogen.